On May 18, 2026, the "2026 Early Commercialization Exploration Report on Brain-Computer Interfaces," jointly initiated by VBdata Think Tank and the Brain-Computer Interface Community, was released. The report systematically reviews the commercialization paths, technological breakthrough directions, and implementation bottlenecks of leading domestic brain-computer interface enterprises. Hangzhou NEUREAL Technology Co., Ltd. was successfully selected as a corporate case study thanks to its BCI+X precision diagnosis and treatment platform for brain disorders and mature commercialization path. It has become a benchmark enterprise for the clinical translation and large-scale implementation of non-invasive brain-computer interfaces, demonstrating its leading strength in the brain-computer interface and digital healthcare sectors.
From Lab to Clinic: A Key Year of Breakthrough for Brain-Computer Interface Commercialization
The report notes that 2026 is a core node for brain-computer interfaces moving from technical exploration to large-scale application. With the resonance of four key factors—policy support, technological breakthroughs, capital inflow, and industrial clustering—China has become a core participant and important driver of the global brain-computer interface ecosystem. Currently, "clinical device registration + hospital procurement" remains the mainstream path with the highest value. However, the non-invasive route, leveraging advantages such as safety, non-invasiveness, ease of operation, and scalability, has achieved implementation in both consumer healthcare and B-end medical scenarios, becoming a key force accelerating the commercialization of brain-computer interfaces.
Meanwhile, the industry still faces systemic challenges including insufficient supply of upstream core components, poor midstream conversion from "technology-clinic-registration," and unclear downstream value perception and pricing. The report clarifies that industrial chain collaboration centered on clinical value is the key to breaking through these bottlenecks.
NEUREAL Technology: BCI+X Reshapes a New Paradigm for Brain Disorder Diagnosis and Treatment
As a national-level "Little Giant" specialized, refined, distinctive, and innovative enterprise focused on AI healthcare + non-invasive brain-computer interfaces, NEUREAL adopts BCI+X as its core strategy. It has built a complete technical system of "precise neural signal induction—target localization—dynamic closed-loop intervention," breaking the limitations of traditional rehabilitation's unidirectional output and providing precise digital intelligent solutions for brain disorders such as stroke, cognitive impairment, Attention Deficit Hyperactivity Disorder (ADHD), depression, and anxiety disorder.
Core Technical Barriers: Precise Capture and Dynamic Adjustment with Significant Clinical Effects
Deep Integration of EEG+AI+VR: Proprietary high-sensitivity EEG electrode caps and an AI Agent hub capture EEG signals in real-time via 1000Hz high-frequency sampling. Cognitive state recognition accuracy exceeds 92%, enabling millisecond-level adaptive scene adjustments.
▲EEG+VR Brain-Computer Interface Virtual Reality Rehabilitation System
Precise Neural Signal Induction Technology:Actively induces brain states to target intervention states, transforming originally randomly fluctuating neural activities into lockable and regulatable neural processes. VR training and neuromodulation are conducted synchronously in this state, enhancing the stability and persistence of intervention effects. Clinical validation shows an approximately 30% increase in intervention effectiveness.
Commercialization Benchmark: Three-Tier Path Covers Full Cycle, Validated Value Across Thousands of Hospitals
NEUREAL has established a three-tier commercialization pathway of "high-end in-hospital diagnosis and treatment—home-based continued rehabilitation—institutional batch services." Its products cover over 1,000 hospitals nationwide, have completed multicenter clinical validation, and demonstrate excellent clinical safety. Cumulative enrollment exceeds 320 subjects, and the company holds 7 domestic and international medical device registration certificates. It is the only enterprise in the industry possessing both precise neural signal induction capabilities and a complete closed-loop diagnosis and treatment system.
Leveraging core technical barriers and a mature commercialization path, NEUREAL Technology has become one of the most mature models for the commercial implementation of non-invasive brain-computer interfaces, providing replicable and scalable practical experience for the industry.
Leading Industry Direction: Breaking Through Brain-Computer Interface Commercialization Driven by Clinical Value
The report emphasizes that the core of brain-computer interface commercialization lies in precisely matching technical characteristics, market demand, and long-term development strategies. Prioritizing clinical necessities and building generalizable technology platforms are key choices. NEUREAL Technology has always been oriented toward unmet clinical needs, deeply integrating brain-computer interfaces, AI, VR, and clinical diagnosis and treatment, perfectly aligning with the report's logic of value creation and industrial chain collaboration for breakthroughs.
This selection for an authoritative industry report highly recognizes NEUREAL Technology's technological innovation, clinical translation, and commercial implementation, while also pointing the direction for the development of non-invasive brain-computer interfaces. In the future, NEUREAL Technology will continue to deepen its BCI+X technical system, expand scenarios such as cognitive rehabilitation, psychiatric care, and developmental disorders in children, driving brain-computer interfaces from research to clinic and from hospitals to homes, helping China's brain-computer interface industry achieve global leadership.
